glp 1 for addiction GLP-1 Drug GLP-1 Medications and Addiction —

Viking selected VK2735 from a series of internally developed dual GLP-1/GIP receptor agonists evaluated as part of a program focused on the development of best-in-class therapies for metabolic diseases

Non-GLP-1 group (79,699 people): 19 cases of NAION

It is generally considered for people who: Have a BMI of 30 or higher, or a BMI of 27 or higher with weight-related conditions such as elevated cholesterol, high blood pressure, or type 2 diabetes

Once you reach a maintenance dosage, you will have regular interval check-ins to discuss your treatment and the appropriateness of new prescriptions

We personalize your GLP1 dose, nutrition, and movement